The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases.
Khan A, Bellio MA, Schulman IH, Levi AD, Longsomboon B, Brooks A, Valasaki K, DiFede DL, Pujol MV, Yavagal DR, Bates KE, Si MS, Kaushal S, Green BA, Anderson KD, Guest JD, Burks SS, Silvera R, Santamaria AJ, Lalwani A, Dietrich WD, Hare JM.
Khan A, et al. Among authors: guest jd.
Front Cell Dev Biol. 2021 Jun 8;9:675738. doi: 10.3389/fcell.2021.675738. eCollection 2021.
Front Cell Dev Biol. 2021.
PMID: 34169074
Free PMC article.